Management of portal hypertension before and after liver transplantation

Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.

Management of portal hypertension before and after liver transplantation

Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.

Dendritic cells in hepatitis and liver transplantation

Radika Soysa, Xia Wu, I. Nicholas Crispe – 28 July 2017 – Dendritic cells (DCs) play a key role in innate immune responses and are also the most effective cells for the activation of T cell immunity. They acquire antigen and process it; then they display it on the cell surface bound in a noncovalent complex with human leukocyte antigen molecules of class I (human leukocyte antigens A, B, and C) and class II (human leukocyte antigen DR).

L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Subscribe to